LONDON, March 9, 2016 /PRNewswire/ --
Thorn Medical PLC ("Thorn" or the "Company"), the international healthcare group, today announces that it has received full approval from the Bahamas Ministry of Health to carry out stem cell research and treatment on humans.
The approval allows Thorn to use human stem cells to cure or treat the full range of conditions and illnesses that humans are prone to.
Jack Kaye, Thorn Medical's Chief Executive, said: "Human stem cells will allow us to regenerate human tissues and have the potential to cure, rather than merely treat, an incredible number of diseases and conditions, from cancers through to quadriplegia.
"We have already done amazing things with animals, such as growing new tendons in race horses, and have achieved similar success in treating a British quadriplegic who can now stand and move both arms, which would have been considered a miracle in the past. The potential to extend stem cell treatments even further is unlimited and we look forward to rising to the challenge of curing many of mankind's ills."
The Ministry of Health, National Ethics Stem Cell Committee for the Bahamas, added "The approval of Thorn Medical's application for human stem cell research and therapy will put the Bahamas firmly at the leading edge of medicine in the developed world. The creation of this new medical industry will not only bring jobs and prosperity to our nation, but will allow us to cure many of the world's most dreaded diseases, which will benefit everyone, wherever they live."
THE DIRECTORS OF THE ISSUER ACCEPT RESPONSIBILITY FOR THE CONTENTS OF THIS ANNOUNCEMENT
Note to Editors
Thorn Medical PLC
Thorn Medical is a trusted expert investor and acceleration partner dedicated to breaking down the barriers to providing more efficient and effective healthcare worldwide.
With a clear focus on improving human wellbeing, it acts as an aggregator of innovative, scientifically-validated medical technology, pharmaceutical products and healthcare services businesses.
It aims to transform organisational performance through delivering best practice flexible management services that streamline operations, reduce costs, encourage cross-fertilisation, expand market reach and enhance return on capital.
Thorn Medical is dedicated to this market, with a global perspective and an understanding at first hand of the evolving challenges that healthcare businesses face in growing successfully.
Thorn Medical understands how to create value for investors, service providers and patients through building a balanced portfolio of pre-and post-revenue companies that specialise in commercialising innovative and medical technologies and services.
Thorn Medical will continue to grow both organically and through acquisitions, continually developing the enterprise and fully addressing the human health cycle and its genetic, environmental, physical and nutritional influencing factors.
Thorn Medical focuses on four areas
- Disease prevention
- Immunity optimisation
- Disease treatment
- Research & development
For further information, please visit Thorn Medical's website http://www.thornmedical.com
Henry Gewanter,Thorn Medical PLC, Tel:+44-(0)7774-228845
